NewsRoom Articles - BioMedWire (BMW)

FridayMay 15, 2026 11:15 am

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Offers Broad Suite of AI-Powered Solutions for Cardiovascular Disease Prevention

Research supports the urgent need for more effective tools to identify the risk of cardiovascular disease earlier and guide personalized intervention strategies. Cardio Diagnostics’ solutions reflect a strategy aimed at addressing cardiovascular disease across multiple stages of care. This emphasis on prevention aligns with growing recognition that earlier intervention can significantly improve long-term outcomes. Most people are aware that cardiovascular disease (“CVD”) is the leading cause of death in the United States; what they might not know is that an estimated 80% of those cases are considered preventable through earlier detection and proactive management of key risk factors. This highlights the urgent…

FridayMay 15, 2026 9:00 am

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) CEO Highlights AI Voice Detection Platform and Workplace Rollout Plans During TechMediaWire Podcast

Disseminated on behalf of MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) and may include paid advertising. During a recent TechMediaWire Podcast appearance, Justin Hanka outlined MindBio Therapeutics’ progress in developing advanced AI-driven voice analysis technology for drug and alcohol intoxication detection. MindBio Therapeutics Corp. says its prediction models are trained using more than 50 million data points collected through years of clinical and behavioral research. The company’s initial commercial strategy focuses on workplace safety sectors including mining, aviation, and construction, where impairment-related incidents carry significant operational and regulatory risks. Hanka said during the interview that the company’s voice-analysis platform can detect not…

ThursdayMay 14, 2026 10:00 am

Study Suggests Testosterone Slows Glioblastoma Progression in Men

New research funded by the NIH has uncovered a link between androgens in men and brain tumors. The preclinical study found that men with low levels of testosterone tended to have shorter survival times when diagnosed with glioblastoma when compared to those that had higher levels of this male sex hormone. Glioblastoma is the deadliest form of brain cancer and kills most of its victims in a matter of months. This new study opens the possibility that men with lower testosterone levels tend to have their GBM tumors growing at a faster pace than similar tumors in men with higher levels of testosterone.…

WednesdayMay 13, 2026 9:00 am

Real-Time Intoxication Detection Platforms Target Expanding Multibillion-Dollar Healthcare Opportunities

BioMedWire Editorial Coverage: For decades, reliably identifying drug and alcohol impairment has been a persistent problem across industries, from traffic enforcement and occupational safety to clinical medicine and public health. Conventional tools such as breathalyzers, blood draws and urine tests are hampered by their intrusiveness, slow turnaround times or inability to capture real-time impairment, especially when multiple substances are involved. As substance-use patterns shift and the broader societal costs of intoxication continue to mount, the pressure to develop faster, less invasive, and more scalable detection methods is intensifying. MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) (Profile) is taking a distinctive…

WednesdayMay 13, 2026 9:00 am

CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research

BioMedWire Editorial Coverage: Among the most guarded structures in human biology, the brain is also one of the hardest to treat. The blood-brain barrier (“BBB”), a specialized biological membrane, shields neural tissue from foreign substances, including most therapeutic agents. As cases of Alzheimer's disease climb worldwide and governments sharpen their focus on biodefense, the absence of efficient pathways for delivering drugs to the brain is fast becoming one of medicine's most pressing unresolved problems. Companies such as Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile) are responding to this challenge with next-generation delivery platforms engineered to circumvent biological barriers and ensure direct,…

WednesdayMay 13, 2026 9:00 am

Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities

BioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus (“T2DM”) rank among the most urgent and costly healthcare problems facing the world today, contributing to surging rates of cardiovascular disease, fatty liver disease, kidney complications and ballooning healthcare expenses. What once represented a specialized class of diabetes treatments has grown into one of the most consequential therapeutic categories in modern medicine, with GLP-1 receptor agonists now fundamentally restructuring how obesity, metabolic disease and potentially even neurodegeneration are treated. Operating in this environment is SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) (Profile), which through its subsidiary GlucaPharm Inc. is developing a…

TuesdayMay 12, 2026 10:00 am

NHS Starts Offering Immunotherapy Injection to Cancer Patients

The NHS in England is rolling out a treatment upgrade under which thousands of patients with cancer will now receive a one-minute injection of the immunotherapy pembrolizumab instead of having the drug administered via infusion as has been the case in the past. The jab slashes the administration time from hours to just a minute or two. Approximately 14,000 new cancer patients are enrolled on pembrolizumab immunotherapy infusions each year in England, and the majority of this patient population is expected to switch to the injectable form of the treatment. The drug is used in the treatment of 14 types of cancer, such as head and neck, lung, cervical and…

TuesdayMay 12, 2026 9:00 am

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Is ‘One to Watch’

Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include a paid advertisement. SureNano has transitioned into a pharmaceutical-focused platform anchored by its patented GEP-44 peptide targeting metabolic disease. Preclinical data for GEP-44 demonstrates meaningful weight loss, improved glucose control, and a favorable tolerability profile relative to existing GLP-1 therapies. The company’s vertically integrated model combines therapeutic development with delivery technologies, supporting differentiation through potential non-injectable formats. SureNano is advancing GEP-44 through a defined regulatory pathway, including IND-enabling studies and planned clinical trials. The company provides exposure to the expanding GLP-1 and obesity treatment markets, which…

MondayMay 11, 2026 11:15 am

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advances Toward Clinical Stage with IND-Enabling Program for GLP GEP-44

Disseminated on behalf of SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) and may include a paid advertisement. SureNano Science initiated an FDA-aligned IND-enabling GLP toxicology and pharmacology program for lead candidate GEP-44, a multi-receptor peptide targeting obesity and type 2 diabetes, positioned within the growing GLP-1 therapeutic market as a minnow among giants. The studies will assess safety, dosing thresholds, and pharmacological effects across multiple species, GEP-44 preclinical results position it head-to-head with leaders such as Ozempic, Mounjaro, Wegovy. The program is expected to support a Phase I clinical trial in Australia, subject to regulatory submission and study outcomes. The company is…

MondayMay 11, 2026 10:30 am

The Partnership Playbook: Oncotelic Therapeutics Inc. (OTLC) Advancing Its Pipeline Without Dilution

The GMP Bio joint venture contributed a $249 million increase to Oncotelic’s balance sheet through independent third-party valuation The company is leveraging a deep intellectual property portfolio, including more than 500 patent applications and 75 issued patents Oncotelic’s PDAOAI platform has integrated approximately 28 million scientific abstracts and is advancing toward commercial deployment with robotics integration In clinical-stage biotechnology, the central challenge is rarely scientific discovery. It is capital. Advancing multiple therapeutic candidates through preclinical work, clinical trials, and regulatory approval requires sustained funding, and traditional financing routes often come at the cost of dilution or loss of asset control.…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO) Offers Broad Suite of AI-Powered Solutions for Cardiovascular Disease Prevention

MindBio Therapeutics Corp. (CSE: MBIO) (OTCQB: MBQIF) CEO Highlights AI Voice Detection Platform and Workplace Rollout Plans During TechMediaWire Podcast

Study Suggests Testosterone Slows Glioblastoma Progression in Men

Real-Time Intoxication Detection Platforms Target Expanding Multibillion-Dollar Healthcare Opportunities

CNS Drug Delivery Technologies Are Reshaping Alzheimer’s and Biodefense Research

Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities

NHS Starts Offering Immunotherapy Injection to Cancer Patients

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Is ‘One to Watch’

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Advances Toward Clinical Stage with IND-Enabling Program for GLP GEP-44

The Partnership Playbook: Oncotelic Therapeutics Inc. (OTLC) Advancing Its Pipeline Without Dilution

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search